We claim:

1. A compound of the following formula:



(I)

or a pharmaceutically acceptable salt thereof, wherein R is an aliphatic or cycloaliphatic amine group.

2. A compound of claim 1, wherein R is a C_1 to C_6 alkyl amine group, C_1 to C_6 dialkyl amine group, piperidino group, piperazino group, pyrrolidino group, pyrrolino group, a morpholino or an amino cyclohexyl derivative.

3. A compound of claim 1, wherein R is pyrrolidino.

4. A pharmaceutical composition comprising a compound of formula (I) and a pharmaceutically acceptable carrier.

5. A method of antagonizing A_{2B} receptors comprising administering to a mammal in need thereof an effective amount of compound of claim 1.

6. A method of treating asthma comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

7. A method of treating diarrhea comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

8. A method of regulating at least one of smooth muscle tone, cell growth, blood vessel growth, intestinal function, and neurosecretion comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

9. A method of treating inflammatory gastrointestinal tract disorders comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

10. A method of treating Alzheimer's disease, Parkinson's disease, dementia, depression, or traumatic brain injury comprising administering to a mammal in need thereof an

Sub A1

effective amount of a compound of claim 1.

11. A method of treating inflammatory diseases comprising administering to a mammal in need thereof an effective amount of a compound of claim 1.

12. A method treating a disease selected from the group consisting of: arthritis, asthma, multiple sclerosis, sepsis, septic shock, endotoxic shock, gram negative shock, toxic shock, hemorrhagic shock, adult respiratory distress syndrome, TNF-enhanced HIV replication, TNF inhibition of AZT and DDI activity, organ transplant rejection, cachexia secondary to cancer, HIV, osteoporosis, infertility from endometriosis, cerebral malaria, bacterial meningitis, adverse effects from amphotericin B treatment, adverse effects from interleukin-2 treatment, adverse effects from OKT3 treatment, or adverse effects from GM-CSF treatment comprising administering to a mammal in need thereof, an effective amount of a compound of claim 1.

Sub A2

13. The method of claim 6, wherein said compound is incorporated with inert carriers into a tablet and administered orally.

14. The method of claim 6, wherein said compound is incorporated with a propellant and a solvent and administered by inhalation of mist.

15. The method of claim 6, wherein said compound is incorporated with a pharmaceutically acceptable carrier and injected into said mammal.

16. The method of claim 7, wherein said compound is incorporated with inert carriers into a tablet and administered orally.

17. The method of claim 7, wherein said compound is incorporated with a propellant and a solvent and administered by inhalation of mist.

18. The method of claim 7, wherein said compound is incorporated with a pharmaceutically acceptable carrier and injected into said mammal.

Sub A3

19. A method of modulating human mast cell function comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

20. A method of treating cardiac disease comprising administering to a patient in need thereof an effective amount of a compound of claim 1.

21. A compound of the following formula:



(II)

or a pharmaceutically acceptable salt thereof.

add A4